Immunome IMNM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$224.59M-9.5% | -$212.39M+27.5% | -$222.74M+27.1% | -$212.39M+19.1% | -$205.11M+11.6% | ||
| $2.46M+21.6% | $2.47M+57.4% | $2.29M+80.4% | $2.11M+118% | $2.02M+289% | ||
| $27.94M+44.8% | $25.69M+63.1% | $23.27M+76.8% | $21.41M+129% | $19.29M+170% | ||
| -$196.5M-28.7% | -$190.92M-72.3% | -$185.03M-115% | -$178.68M— | -$152.68M— | ||
| $9.02M+4.0% | $9.69M+35.0% | $6.81M+6.5% | $7.24M+47.9% | $8.67M+200% | ||
| —— | —— | —— | —— | —— | ||
| $47.7M— | $64.8M— | —— | —— | —— | ||
| $478.05M+161% | $640.41M+166% | $227.7M-17.5% | $182.62M-45.7% | $183.31M-45.4% | ||
| —— | —— | —— | —— | —— | ||
| -$205.52M-27.4% | -$200.6M-70.1% | -$191.84M-107% | -$185.92M— | -$161.35M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's cash flow data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.